trial

Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics

NCTId NCT02037074
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 40 (actual)
Sponsored by FORUM Pharmaceuticals Inc
Primary completion 2014-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
40 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2014-06
Primary completion
2014-12
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Drug: EVP-6308

Sponsors

FORUM Pharmaceuticals IncLead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE1
Primary Completion Date
2014-12
Status
COMPLETED
relationships
The graph out of here
drug
Drug: EVP-6308
drug
lead_sponsor
FORUM Pharmaceuticals Inc
company
indication
Schizophrenia
indication
Schizophrenia
indication